SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Osato, M. Articles by Ito, Y. Search for Related Content PubMed PubMed Citation Articles by Osato, M. Articles by Ito, Y. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 93 No. 6 (March 15), 1999: pp. 1817-1824 RAPID COMMUNICATION Biallelic and Heterozygous Point Mutations in the Runt Domain of the AML1/PEBP2B Gene Associated With Myeloblastic Leukemias Motomi Osato, Norio Asou, Essam Abdalla, Koyu Hoshino, Hiroshi Yamasaki, Toshiya Okubo, Hitoshi Suzushima, Kiyoshi Takatsuki, Tomohiko Kanno, Katsuya Shigesada, and Yoshiaki Ito From Second Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan; and the Departments of Viral Oncology and of Genetics and Molecular Biology, Institute for Virus Research, Kyoto University, Kyoto, Japan. The AML1 gene encoding the DNA-binding -subunit in the Runt domain family of heterodimeric transcription factors has been noted for its frequent involvement in chromosomal translocations associated with leukemia. Using reverse transcriptase-polymerase chain reaction (RT-PCR) combined with nonisotopic RNase cleavage assay (NIRCA), we found point mutations of the AML1 gene in 8 of 160 leukemia patients: silent mutations, heterozygous missense mutations, and biallelic nonsense or frameshift mutations in 2, 4, and 2 cases, respectively. The mutations were all clustered within the Runt domain. Missense mutations identified in 3 patients showed neither DNA binding nor transactivation, although being active in heterodimerization. These defective missense mutants may be relevant to the predisposition or progression of leukemia. On the other hand, the biallelic nonsense mutants encoding truncated AML1 proteins lost almost all functions examined and may play a role in leukemogenesis leading to acute myeloblastic leukemia. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: X.-Z. Chi, J. Kim, Y.-H. Lee, J.-W. Lee, K.-S. Lee, H. Wee, W.-J. Kim, W.-Y. Park, B.-C. Oh, G. S. Stein, et al. Runt-Related Transcription Factor RUNX3 Is a Target of MDM2-Mediated Ubiquitination Cancer Res., October 15, 2009; 69(20): 8111 - 8119. [Abstract] [Full Text] [PDF] Y.-H. Kuo, S. K. Zaidi, S. Gornostaeva, T. Komori, G. S. Stein, and L. H. Castilla Runx2 induces acute myeloid leukemia in cooperation with Cbf{beta}-SMMHC in mice Blood, April 2, 2009; 113(14): 3323 - 3332. [Abstract] [Full Text] [PDF] S. Malinge, S. Izraeli, and J. D. Crispino Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome Blood, March 19, 2009; 113(12): 2619 - 2628. [Abstract] [Full Text] [PDF] R. Bakshi, S. K. Zaidi, S. Pande, M. Q. Hassan, D. W. Young, M. Montecino, J. B. Lian, A. J. van Wijnen, J. L. Stein, and G. S. Stein The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes J. Cell Sci., December 1, 2008; 121(23): 3981 - 3990. [Abstract] [Full Text] [PDF] C. J. Owen, C. L. Toze, A. Koochin, D. L. Forrest, C. A. Smith, J. M. Stevens, S. C. Jackson, M.-C. Poon, G. D. Sinclair, B. Leber, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy Blood, December 1, 2008; 112(12): 4639 - 4645. [Abstract] [Full Text] [PDF] H.-J. Wee, D. C.-C. Voon, S.-C. Bae, and Y. Ito PEBP2-{beta}/CBF-{beta}-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis Blood, November 1, 2008; 112(9): 3777 - 3787. [Abstract] [Full Text] [PDF] Y. Satoh, I. Matsumura, H. Tanaka, S. Ezoe, K. Fukushima, M. Tokunaga, M. Yasumi, H. Shibayama, M. Mizuki, T. Era, et al. AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells J. Biol. Chem., October 31, 2008; 283(44): 30045 - 30056. [Abstract] [Full Text] [PDF] N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura AML1 mutations induced MDS and MDS/AML in a mouse BMT model Blood, April 15, 2008; 111(8): 4297 - 4308. [Abstract] [Full Text] [PDF] M. Ichikawa, S. Goyama, T. Asai, M. Kawazu, M. Nakagawa, M. Takeshita, S. Chiba, S. Ogawa, and M. Kurokawa AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis J. Immunol., April 1, 2008; 180(7): 4402 - 4408. [Abstract] [Full Text] [PDF] C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance Blood, April 1, 2008; 111(7): 3735 - 3741. [Abstract] [Full Text] [PDF] K. Kirito, K. Sakoe, D. Shinoda, Y. Takiyama, K. Kaushansky, and N. Komatsu A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies Haematologica, January 1, 2008; 93(1): 155 - 156. [Abstract] [Full Text] [PDF] F. Dicker, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia Blood, August 15, 2007; 110(4): 1308 - 1316. [Abstract] [Full Text] [PDF] D. Li, K. K. Sinha, M. A. Hay, C. R. Rinaldi, Y. Saunthararajah, and G. Nucifora RUNX1-RUNX1 Homodimerization Modulates RUNX1 Activity and Function J. Biol. Chem., May 4, 2007; 282(18): 13542 - 13551. [Abstract] [Full Text] [PDF] N. Asou, M. Yanagida, L. Huang, M. Yamamoto, K. Shigesada, H. Mitsuya, Y. Ito, and M. Osato Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia Blood, May 1, 2007; 109(9): 4023 - 4027. [Abstract] [Full Text] [PDF] C. Miething, R. Grundler, C. Mugler, S. Brero, J. Hoepfl, J. Geigl, M. R. Speicher, O. Ottmann, C. Peschel, and J. Duyster Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment PNAS, March 13, 2007; 104(11): 4594 - 4599. [Abstract] [Full Text] [PDF] J. Cammenga, B. Niebuhr, S. Horn, U. Bergholz, G. Putz, F. Buchholz, J. Lohler, and C. Stocking RUNX1 DNA-Binding Mutants, Associated with Minimally Differentiated Acute Myelogenous Leukemia, Disrupt Myeloid Differentiation Cancer Res., January 15, 2007; 67(2): 537 - 545. [Abstract] [Full Text] [PDF] J. R. Biggs, L. F. Peterson, Y. Zhang, A. S. Kraft, and D.-E. Zhang AML1/RUNX1 Phosphorylation by Cyclin-Dependent Kinases Regulates the Degradation of AML1/RUNX1 by the Anaphase-Promoting Complex Mol. Cell. Biol., October 15, 2006; 26(20): 7420 - 7429. [Abstract] [Full Text] [PDF] I. Moreno-Miralles, L. Pan, J. Keates-Baleeiro, K. Durst-Goodwin, C. Yang, H.-G. Kim, M. A. Thompson, C. A. Klug, J. L. Cleveland, and S. W. Hiebert The inv(16) Cooperates with ARF Haploinsufficiency to Induce Acute Myeloid Leukemia J. Biol. Chem., December 2, 2005; 280(48): 40097 - 40103. [Abstract] [Full Text] [PDF] M. Kundu, S. Compton, L. Garrett-Beal, T. Stacy, M. F. Starost, M. Eckhaus, N. A. Speck, and P. P. Liu Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma Blood, November 15, 2005; 106(10): 3621 - 3624. [Abstract] [Full Text] [PDF] S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF] F. Rosenbauer, S. Koschmieder, U. Steidl, and D. G. Tenen Effect of transcription-factor concentrations on leukemic stem cells Blood, September 1, 2005; 106(5): 1519 - 1524. [Abstract] [Full Text] [PDF] J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype Blood, July 15, 2005; 106(2): 494 - 504. [Abstract] [Full Text] [PDF] J. R. Biggs, Y. Zhang, L. F. Peterson, M. Garcia, D.-E. Zhang, and A. S. Kraft Phosphorylation of AML1/RUNX1 Regulates Its Degradation and Nuclear Matrix Association Mol. Cancer Res., July 1, 2005; 3(7): 391 - 401. [Abstract] [Full Text] [PDF] P. G. Heller, A. C. Glembotsky, M. J. Gandhi, C. L. Cummings, C. J. Pirola, R. F. Marta, L. I. Kornblihtt, J. G. Drachman, and F. C. Molinas Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation Blood, June 15, 2005; 105(12): 4664 - 4670. [Abstract] [Full Text] [PDF] Y. Fukushima-Nakase, Y. Naoe, I. Taniuchi, H. Hosoi, T. Sugimoto, and T. Okuda Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development Blood, June 1, 2005; 105(11): 4298 - 4307. [Abstract] [Full Text] [PDF] J. C. Mulloy, V. Jankovic, M. Wunderlich, R. Delwel, J. Cammenga, O. Krejci, H. Zhao, P. J. M. Valk, B. Lowenberg, and S. D. Nimer AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion PNAS, March 15, 2005; 102(11): 4016 - 4021. [Abstract] [Full Text] [PDF] F. M. Theriault, H. N. Nuthall, Z. Dong, R. Lo, F. Barnabe-Heider, F. D. Miller, and S. Stifani Role for Runx1 in the Proliferation and Neuronal Differentiation of Selected Progenitor Cells in the Mammalian Nervous System J. Neurosci., February 23, 2005; 25(8): 2050 - 2061. [Abstract] [Full Text] [PDF] L. A. Nguyen, P. P. Pandolfi, Y. Aikawa, Y. Tagata, M. Ohki, and I. Kitabayashi Physical and functional link of the leukemia-associated factors AML1 and PML Blood, January 1, 2005; 105(1): 292 - 300. [Abstract] [Full Text] [PDF] W. Sun and J. R. Downing Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors Blood, December 1, 2004; 104(12): 3565 - 3572. [Abstract] [Full Text] [PDF] D. Helbling, B. U. Mueller, N. A. Timchenko, A. Hagemeijer, M. Jotterand, S. Meyer-Monard, A. Lister, J. D. Rowley, B. Huegli, M. F. Fey, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin PNAS, September 7, 2004; 101(36): 13312 - 13317. [Abstract] [Full Text] [PDF] D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation Blood, September 1, 2004; 104(5): 1474 - 1481. [Abstract] [Full Text] [PDF] G. Huang, K. Shigesada, H.-J. Wee, P. P. Liu, M. Osato, and Y. Ito Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera Blood, April 15, 2004; 103(8): 3200 - 3207. [Abstract] [Full Text] [PDF] H. Harada, Y. Harada, H. Niimi, T. Kyo, A. Kimura, and T. Inaba High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia Blood, March 15, 2004; 103(6): 2316 - 2324. [Abstract] [Full Text] [PDF] Y. Imai, M. Kurokawa, Y. Yamaguchi, K. Izutsu, E. Nitta, K. Mitani, M. Satake, T. Noda, Y. Ito, and H. Hirai The Corepressor mSin3A Regulates Phosphorylation-Induced Activation, Intranuclear Location, and Stability of AML1 Mol. Cell. Biol., February 1, 2004; 24(3): 1033 - 1043. [Abstract] [Full Text] [PDF] L. Sun, G. Mao, and A. K. Rao Association of CBFA2 mutation with decreased platelet PKC-{theta} and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation Blood, February 1, 2004; 103(3): 948 - 954. [Abstract] [Full Text] [PDF] F.-Q. Li, R. E. Person, K.-I. Takemaru, K. Williams, K. Meade-White, A. H. Ozsahin, T. Gungor, R. T. Moon, and M. Horwitz Lymphoid Enhancer Factor-1 Links Two Hereditary Leukemia Syndromes through Core-binding Factor {alpha} Regulation of ELA2 J. Biol. Chem., January 23, 2004; 279(4): 2873 - 2884. [Abstract] [Full Text] [PDF] S. Gurbuxani, P. Vyas, and J. D. Crispino Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome Blood, January 15, 2004; 103(2): 399 - 406. [Abstract] [Full Text] [PDF] M. Nishimura, Y. Fukushima-Nakase, Y. Fujita, M. Nakao, S. Toda, N. Kitamura, T. Abe, and T. Okuda VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development Blood, January 15, 2004; 103(2): 562 - 570. [Abstract] [Full Text] [PDF] D. G. Gilliland, C. T. Jordan, and C. A. Felix The Molecular Basis of Leukemia Hematology, January 1, 2004; 2004(1): 80 - 97. [Abstract] [Full Text] [PDF] T. J. Ley, P. J. Minx, M. J. Walter, R. E. Ries, H. Sun, M. McLellan, J. F. DiPersio, D. C. Link, M. H. Tomasson, T. A. Graubert, et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes PNAS, November 25, 2003; 100(24): 14275 - 14280. [Abstract] [Full Text] [PDF] Z. Li, J. Yan, C. J. Matheny, T. Corpora, J. Bravo, A. J. Warren, J. H. Bushweller, and N. A. Speck Energetic Contribution of Residues in the Runx1 Runt Domain to DNA Binding J. Biol. Chem., August 29, 2003; 278(35): 33088 - 33096. [Abstract] [Full Text] [PDF] H. Hirai Molecular Mechanisms of Myelodysplastic Syndrome Jpn. J. Clin. Oncol., April 1, 2003; 33(4): 153 - 160. [Abstract] [Full Text] [PDF] M. L. Kalev-Zylinska, J. A. Horsfield, M. V. C. Flores, J. H. Postlethwait, M. R. Vitas, A. M. Baas, P. S. Crosier, and K. E. Crosier Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis Development, March 6, 2003; 129(8): 2015 - 2030. [Abstract] [Full Text] [PDF] C. Roumier, V. Eclache, M. Imbert, F. Davi, E. MacIntyre, R. Garand, P. Talmant, P. Lepelley, J. L. Lai, O. Casasnovas, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH) Blood, February 15, 2003; 101(4): 1277 - 1283. [Abstract] [Full Text] [PDF] H. Harada, Y. Harada, H. Tanaka, A. Kimura, and T. Inaba Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia Blood, January 15, 2003; 101(2): 673 - 680. [Abstract] [Full Text] [PDF] R. K. Vangala, M. S. Heiss-Neumann, J. S. Rangatia, S. M. Singh, C. Schoch, D. G. Tenen, W. Hiddemann, and G. Behre The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia Blood, January 1, 2003; 101(1): 270 - 277. [Abstract] [Full Text] [PDF] S. Wotton, M. Stewart, K. Blyth, F. Vaillant, A. Kilbey, J. C. Neil, and E. R. Cameron Proviral Insertion Indicates a Dominant Oncogenic Role for Runx1/AML-1 in T-Cell Lymphoma Cancer Res., December 15, 2002; 62(24): 7181 - 7185. [Abstract] [Full Text] [PDF] C. Lamandin, C. Sagot, C. Roumier, P. Lepelley, S. De Botton, A. Cosson, P. Fenaux, and C. Preudhomme Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood, December 15, 2002; 100(13): 4680 - 4680. [Full Text] [PDF] B. U. Mueller, T. Pabst, M. Osato, N. Asou, L. M. Johansen, M. D. Minden, G. Behre, W. Hiddemann, Y. Ito, and D. G. Tenen Heterozygous PU.1 mutations are associated with acute myeloid leukemia Blood, July 18, 2002; 100(3): 998 - 1007. [Abstract] [Full Text] [PDF] S. Schnittger, C. Schoch, M. Dugas, W. Kern, P. Staib, C. Wuchter, H. Loffler, C. M. Sauerland, H. Serve, T. Buchner, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood, June 17, 2002; 100(1): 59 - 66. [Abstract] [Full Text] [PDF] H. Leroy, C. Roumier, N. Grardel-Duflos, E. Macintyre, P. Lepelley, P. Fenaux, and C. Preudhomme Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes Blood, May 15, 2002; 99(10): 3848 - 3850. [Abstract] [Full Text] [PDF] J. Brown, M. Jawad, S. R. F. Twigg, K. Saracoglu, A. Sauerbrey, A. E. Thomas, R. Eils, J. Harbott, and L. Kearney A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay Blood, April 1, 2002; 99(7): 2526 - 2531. [Abstract] [Full Text] [PDF] J. Michaud, F. Wu, M. Osato, G. M. Cottles, M. Yanagida, N. Asou, K. Shigesada, Y. Ito, K. F. Benson, W. H. Raskind, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis Blood, February 15, 2002; 99(4): 1364 - 1372. [Abstract] [Full Text] [PDF] H. N. Nuthall, J. Husain, K. W. McLarren, and S. Stifani Role for Hes1-Induced Phosphorylation in Groucho-Mediated Transcriptional Repression Mol. Cell. Biol., January 15, 2002; 22(2): 389 - 399. [Abstract] [Full Text] [PDF] A. Buijs, P. Poddighe, R. van Wijk, W. van Solinge, E. Borst, L. Verdonck, A. Hagenbeek, P. Pearson, and H. Lokhorst A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies Blood, November 1, 2001; 98(9): 2856 - 2858. [Abstract] [Full Text] [PDF] D. A. Sweetser, C.-S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, et al. Loss of heterozygosity in childhood de novo acute myelogenous leukemia Blood, August 15, 2001; 98(4): 1188 - 1194. [Abstract] [Full Text] [PDF] J. D. Miller, T. Stacy, P. P. Liu, and N. A. Speck Core-binding factor {beta} (CBF{beta}), but not CBF{beta}-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBF{beta}-deficient embryonic stem cells Blood, April 15, 2001; 97(8): 2248 - 2256. [Abstract] [Full Text] [PDF] R. Hromas, T. Busse, A. Carroll, D. Mack, R. Shopnick, D.-E. Zhang, H. Nakshatri, and K. Richkind Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein Blood, April 1, 2001; 97(7): 2168 - 2170. [Abstract] [Full Text] [PDF] Y. Imai, M. Kurokawa, K. Izutsu, A. Hangaishi, K. Takeuchi, K. Maki, S. Ogawa, S. Chiba, K. Mitani, and H. Hirai Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis Blood, November 1, 2000; 96(9): 3154 - 3160. [Abstract] [Full Text] [PDF] K. Shimizu, I. Kitabayashi, N. Kamada, T. Abe, N. Maseki, K. Suzukawa, and M. Ohki AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon Blood, July 1, 2000; 96(1): 288 - 296. [Abstract] [Full Text] [PDF] T. Okuda, K. Takeda, Y. Fujita, M. Nishimura, S. Yagyu, M. Yoshida, S. Akira, J. R. Downing, and T. Abe Biological Characteristics of the Leukemia-Associated Transcriptional Factor AML1 Disclosed by Hematopoietic Rescue of AML1-Deficient Embryonic Stem Cells by Using a Knock-in Strategy Mol. Cell. Biol., January 1, 2000; 20(1): 319 - 328. [Abstract] [Full Text] E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah Achievements in Understanding and Treatment of Myelodysplastic Syndromes Hematology, January 1, 2000; 2000(1): 110 - 132. [Abstract] [Full Text] [PDF] Y.-Y. Tang, J. Shi, L. Zhang, A. Davis, J. Bravo, A. J. Warren, N. A. Speck, and J. H. Bushweller Energetic and Functional Contribution of Residues in the Core Binding Factor beta (CBFbeta ) Subunit to Heterodimerization with CBFalpha J. Biol. Chem., December 8, 2000; 275(50): 39579 - 39588. [Abstract] [Full Text] [PDF]

	Copyright © 1999 by American Society of Hematology         Online ISSN: 1528-0020